Intellectual Property Strategy in the Global Cosmetics Industry A Soap Opera

Dietmar Harhoff

University of Munich and CEPR

Bronwyn H. Hall

University of California, Berkeley and NBER


Why are we doing this?

- importance of IP and IP policy for innovation
- increased corporate use of various IP strategies
 - litigation, opposition
 - deep purse, cost of FUD (see Lerner, Hall and Ziedonis)
- patent systems make mistakes how to fix them at lowest cost?


Why this industry?

- mundane industry branding is importantaverage advertising intensity around10%
- R&D intensities ~2% much lower than in pharmaceuticals and biotechnology, but not trivially small
- high patent opposition activity even though not a high-technology industry – why?

Advertising and R&D Spending - Large Toiletries Firms




EPO Patenting in A61K 7





Patent examination at the EPO




Opposition Proceedings – Some Institutional Detail


- centralized proceedings, two instances (opposition and appeal) at the EPO
- modeled on the opposition mechanism in the German Patent System
- cost: 15,000-25,000 Euros
- subsequent litigation is at the national level (at much higher cost)
- any third party can oppose a patent grant within 9 months after the grant date
- once initiated by the opponent, opposed and opposing parties cannot settle "out of court"
- overall rate 7%
 - ~30 times more likeley than US patent re-examination
 - ~10 times more likely than US patent litigation CEPR/IFS Conference Nov 02

Incidence of opposition

EPO Opposition Rates 1983-1999



Opposition Proceedings – Some Institutional Detail



A Simple Model

When would we expect to see opposition?

Consider two cases

- Successful opposition transforms monopoly to duopoly (entrant opposition)
- Successful opposition preserves monopoly (incumbent opposition)

A Simple Model

When would we expect to see opposition?

threat points

$$T_O = p_O \Pi^D - c_O$$

$$T_P = p_P \Pi^D + (1 - p_P) \Pi^M - c_P$$

cooperative solution (settlement)

$$CV = \Pi^S - S$$

Opposition will occur if the cooperative surplus is smaller than the sum of the threat points.

$$(\Pi^{M} - 2\Pi^{D})(1 - p_{P}) + (p_{O} - p_{P})\Pi^{D} + (S - c_{O} - c_{P}) \geq (\Pi^{S} - 2\Pi^{D})$$


$$(\Pi^{M} - 2\Pi^{D})(1 - p_{P}) + (p_{O} - p_{P})\Pi^{D} + (S - c_{O} - c_{P}) \geq (\Pi^{S} - 2\Pi^{D})$$

$$(Ost cost advantage of the opponent of settlement)$$

$$(Ost cost advantage of settlement)$$

A Simple Model

When would we expect to see opposition?



Reduced form implications

The likelihood of opposition increases with ...


- ... increasing stakes (more valuable patents)
- ... diverging expectations
- ... degree of asymmetric information
- ... decreasing cost advantage of settlement vs. opposition proceedings relative to settlement costs (likely to be low in this case)

Data

- 8,501 EPO patent applications with A61K
 7 as main or auxiliary classification
 (1978-2001)
- our sample: all 3,548 patents granted by Dec. 1995
- 523, or 14.7%, were opposed
- multiple oppositions:
 - 68% once
 - 20% twice
 - 12% three or more times

Patenting over time

Patent Application Rates for Selected Firms (Granted Patents) 1978-1995



Enter the main players

Most Active Patenting Firms in Cosmetics								
1978-2000								
Opponent	Number of Patents Granted	Oppositions Filed	Own Patents Opposed	Ratio				
HENKEL	221	207	23	9.00				
GOLDWELL	33	93	16	5.81				
WELLA	110	60	21	2.86				
BASF	65	15	8	1.88				
MERCK	23	5	4	1.25				
COLGATE-PALMOLIVE	43	16	13	1.23				
BEIERSDORF	28	9	8	1.13				
BRISTOL-MYERS SQUIBB	31	7	7	1.00				
PROCTER & GAMBLE	161	41	80	0.51				
L'OREAL	538	53	141	0.38				
SMITHKLINE BEECHAM	40	6	18	0.33				
UNILEVER	274	25	91	0.27				
KAO	177	0	43	0.00				
Total for all firms	4205	848	573	1.48				

Empirical results – who is attacking whom?

- See Table 8 in the paper
- Henkel, Goldwell and Wella account for the lion share of oppositions filed
- oppositions hit mostly P&G, Unilever and L'Oreal

Value correlates

- Number of designated EPC countries
- Number of claims
- Citations:
 - Number of backward A-cites to patents
 - Number of backward XY-cites to patents
 - Number of backward A-cites to scientific lit.
 - Number of backward XY-cites to scientific lit.
 - Number of forward A-cites
 - Number of forward XY-cites
- PCT application
- Accelerated exam requested
- Non-corporate applicant; university applicant

Empirical results – opposition probability

- Table 9 descriptive stats on oppositions by firm
- Table 10 simple probit for opposition probability.
 - opposition likelihood increases as value correlates increase
 - aggressive opponents (Henkel, Wella, Goldwell) have lower rates controlling for value correlates
 - P&G and Unilever face higher rates
 - Specific product classes:
 - cosmetics NEC; soaps; deodorants; sun/insect lotions, dental care
 - haircare (+12 percent)
 - perfumes, makeup, nailcare (-8 percent)

Opposition outcomes

- Table 11 opposition outcomes compared to other technologies
 - Slightly less likely to be rejected, more likely to result in patent revocation
- Table 12 outcomes by nationality of firm

	Non-German	German	Non-German	German	Henkel is	
Outcome	Patentholder	Patentholder	Opposer	Opposer	Opposer	All firms
Opposition rejected	17.9%	38.5%	28.3%	19.2%	12.4%	14.9%
Patent amended	34.0%	29.5%	32.8%	33.0%	26.4%	21.6%
Patent revoked	45.7%	32.0%	37.4%	45.8%	58.9%	27.8%
Other	2.4%	0.0%	1.5%	2.0%	2.3%	1.2%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	65.5%

Conclusions

- high opposition rate due mostly to actions of a few players in the hair care industry
- more valuable patents are more likely to be attacked (as theory suggests)
- new citation measures do provide additional information

Questions

- Is this legitimate opposition due to asymmetric information or harassment of large firms by established firms that have experience with the use of opposition?
- Is Henkel the Texas Instruments of the hair care industry?
 - We don't really know, although the positive outcomes for German firms do suggest they are bringing some prior art to bear.

Further research

- model interaction between portfolio of opponent i and new patent
- are Henkel opposition cases taking longer?
- US data as controls
- add firm-level data